Adjuvant enzalutamide (Enza) for men with high-risk prostate cancer (HRPCa) after radical prostatectomy (RP).

被引：0
|
作者：
Ornstein, Moshe Chaim
Stephenson, Andrew J.
Elson, Paul
Tyler, Allison Janine
Profusek, Pam
Grivas, Petros
Rini, Brian I.
Klein, Eric A.
Garcia, Jorge A.
机构：
[1] Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA
[2] Cleveland Clin, Glickman Urol & Kidney Inst, Cleveland, OH 44106 USA
[3] Cleveland Clin, Cleveland, OH 44106 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.5071
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5071
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy
    A S Kibel
    J B Nelson
    Prostate Cancer and Prostatic Diseases, 2007, 10 : 119 - 126
  • [32] Adjuvant and salvage treatment options for patients with high-risk prostate cancer treated with radical prostatectomy
    Kibel, A. S.
    Nelson, J. B.
    PROSTATE CANCER AND PROSTATIC DISEASES, 2007, 10 (02) : 119 - 126
  • [33] Adjuvant vs Salvage Radiation Therapy for High-Risk Prostate Cancer Following Radical Prostatectomy
    MacDuffie, Emily
    D'Amico, Anthony V.
    JAMA ONCOLOGY, 2020, 6 (08) : 1165 - 1166
  • [34] Phase II Randomized Study of Salvage Radiation Therapy Plus Enzalutamide or Placebo for High-Risk Prostate-Specific Antigen Recurrent Prostate Cancer After Radical Prostatectomy: The SALV-ENZA Trial
    Tran, Phuoc T.
    Lowe, Kathryn
    Tsai, Hua-Ling
    Song, Daniel Y.
    Hung, Arthur Y.
    Hearn, Jason W. D.
    Miller, Steven
    Proudfoot, James A.
    Deek, Matthew P.
    Phillips, Ryan
    Lotan, Tamara
    Paller, Channing J.
    Marshall, Catherine H.
    Markowski, Mark
    Dipasquale, Shirl
    Denmeade, Samuel
    Carducci, Michael
    Eisenberger, Mario
    DeWeese, Theodore L.
    Orton, Matthew
    Deville, Curtiland
    Davicioni, Elai
    Liauw, Stanley L.
    Heath, Elisabeth I.
    Greco, Stephen
    Desai, Neil B.
    Spratt, Daniel E.
    Feng, Felix
    Wang, Hao
    Beer, Tomasz M.
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (06) : 1307 - +
  • [35] Adjuvant Leuprolide With or Without Docetaxel in Patients With High-Risk Prostate Cancer After Radical Prostatectomy (TAX-3501)
    Schweizer, Michael T.
    Huang, Peng
    Kattan, Michael W.
    Kibel, Adam S.
    de Wit, Ronald
    Sternberg, Cora N.
    Epstein, Jonathan I.
    Eisenberger, Mario A.
    CANCER, 2013, 119 (20) : 3610 - 3618
  • [36] Adjuvant weekly docetaxel (D) for high-risk prostate cancer patients (pts) after radical prostatectomy (RP): Preliminary data of a multicenter pilot trial.
    Rosenbaum, E
    Kibel, A
    Roth, BJ
    Wilding, G
    Dreicer, R
    Chatta, G
    Petrylak, D
    Dipaola, RS
    Beer, TM
    Eisenberger, MA
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 418S - 418S
  • [37] Adjuvant Androgen Deprivation for High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921 Study
    Dorff, Tanya B.
    Flaig, Thomas W.
    Tangen, Catherine M.
    Hussain, Maha H. A.
    Swanson, Gregory P.
    Wood, David P., Jr.
    Sakr, Wael A.
    Dawson, Nancy A.
    Haas, Naomi B.
    Crawford, E. David
    Vogelzang, Nicholas J.
    Thompson, Ian M.
    Glode, L. Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2040 - 2045
  • [38] Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer
    Montorsi, Francesco
    Mazzone, Elio
    Gandaglia, Giorgio
    Stabile, Armando
    Salonia, Andrea
    Briganti, Alberto
    JOURNAL OF UROLOGY, 2022, 208 (01): : 223 - 224
  • [39] Radical prostatectomy for high-risk prostate cancer | Opinion: YES
    Reis, Leonardo O.
    Montenegro, Rodrigo
    Quoc-Dien Trinh
    INTERNATIONAL BRAZ J UROL, 2019, 45 (03): : 424 - 427
  • [40] High-risk prostate cancer: The oncological efficiency of radical prostatectomy
    Veliyev, E. I.
    Sokolov, E. A.
    Loran, O. B.
    Petrov, S. B.
    ONKOUROLOGIYA, 2014, 10 (01): : 53 - 57
12345